Literature DB >> 15858808

Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy.

Carla Colombo1, Diana Costantini, Alessia Rocchi, Lisa Cariani, Maria Laura Garlaschi, Silvia Tirelli, Giliola Calori, Elena Copreni, Massimo Conese.   

Abstract

It is not known whether cytokine levels in sputum may be used as outcome measures after parenteral antibiotic therapy in cystic fibrosis (CF) patients. Here, we assessed the effects of antibiotic therapy on cytokine levels in sputum and serum obtained from young CF patients. Thirty-two CF patients (14 females; mean age, 18.6 years; range, 11.4-35.7 years), consecutively admitted at the CF Center of Milan for parenteral antibiotic therapy during pulmonary exacerbation, were enrolled in the study. Before and after 21 days (range, 5-41) of intravenous antibiotic treatment, all patients underwent routine laboratory determinations (including white blood cell (WBC) count and C-reactive protein (CRP)), a chest X-ray, pulmonary function tests (forced expiratory volume in 1 sec (FEV1) and forced vital capacity (FVC) as % predicted), and sputum cultures. Interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor (TNF)-alpha levels in serum and sputum samples were determined by means of immunometric assays. After therapy, FEV1 and FVC significantly improved (median increase of 7.5% and 8.5% predicted, respectively), while CRP and WBC count were significantly decreased (median values from 14 to 5.5 mg/dl and from 8,350 to 7,400 n/mm3, respectively). While levels of IL-6 and IL-10 in sputum were generally undetectable, IL-8 and TNF-alpha were always measurable, and IL-8 levels significantly decreased after antibiotic treatment (median values from 7,165 to 5,415 pg/ml). Following antibiotic therapy, IL-8 and TNF-alpha levels in sputum were inversely related with both FEV(1) and FVC. In conclusion, TNF-alpha and IL-8 levels in sputum of young CF patients with pulmonary exacerbation were always detectable and may be useful, noninvasive outcome measures to assess response to therapy in CF patients. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858808     DOI: 10.1002/ppul.20237

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  20 in total

1.  Sputum proteomics in inflammatory and suppurative respiratory diseases.

Authors:  Robert D Gray; Gordon MacGregor; Donald Noble; Margaret Imrie; Maria Dewar; A Christopher Boyd; J Alastair Innes; David J Porteous; Andrew P Greening
Journal:  Am J Respir Crit Care Med       Date:  2008-06-19       Impact factor: 21.405

2.  Mucoid Pseudomonas aeruginosa and regional inflammation in the cystic fibrosis lung.

Authors:  Sankalp Malhotra; Don Hayes; Daniel J Wozniak
Journal:  J Cyst Fibros       Date:  2019-04-26       Impact factor: 5.482

Review 3.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

4.  Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.

Authors:  Scott D Sagel; Valeria Thompson; James F Chmiel; Gregory S Montgomery; Samya Z Nasr; Elizabeth Perkett; Milene T Saavedra; Bonnie Slovis; Margaret M Anthony; Peggy Emmett; Sonya L Heltshe
Journal:  Ann Am Thorac Soc       Date:  2015-05

Review 5.  Immunometabolism in biofilm infection: lessons from cancer.

Authors:  Rasoul Mirzaei; Niloofar Sabokroo; Yaghoub Ahmadyousefi; Hamid Motamedi; Sajad Karampoor
Journal:  Mol Med       Date:  2022-01-29       Impact factor: 6.354

6.  Exhaled breath condensate adenosine tracks lung function changes in cystic fibrosis.

Authors:  Charles R Esther; Bonnie M Olsen; Feng-Chang Lin; Jason Fine; Richard C Boucher
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-01-25       Impact factor: 5.464

Review 7.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 8.  Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.

Authors:  Geraint B Rogers; Lucas R Hoffman; Matt W Johnson; Nicole Mayer-Hamblett; Jürgen Schwarze; Mary P Carroll; Kenneth D Bruce
Journal:  Expert Rev Mol Diagn       Date:  2011-03       Impact factor: 5.225

9.  Impairment in inflammasome signaling by the chronic Pseudomonas aeruginosa isolates from cystic fibrosis patients results in an increase in inflammatory response.

Authors:  Melissa S Phuong; Rafael E Hernandez; Daniel J Wolter; Lucas R Hoffman; Subash Sad
Journal:  Cell Death Dis       Date:  2021-03-04       Impact factor: 8.469

10.  Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.

Authors:  Edith T Zemanick; J Kirk Harris; Brandie D Wagner; Charles E Robertson; Scott D Sagel; Mark J Stevens; Frank J Accurso; Theresa A Laguna
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.